NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma Article

Sloan, Andrew E, Winter, Kathryn, Gilbert, Mark R et al. (2024). NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma . NEURO-ONCOLOGY, 26(9), 1628-1637. 10.1093/neuonc/noae058

cited authors

  • Sloan, Andrew E; Winter, Kathryn; Gilbert, Mark R; Aldape, Kenneth; Choi, Serah; Wen, Patrick Y; Butowski, Nicholas; Iwamoto, Fabio M; Raval, Raju R; Voloschin, Alfredo D; Kamiya-Matsuoka, Carlos; Won, Minhee; Mehta, Minesh P

sustainable development goals

authors

publication date

  • June 19, 2024

published in

keywords

  • CANCER
  • Clinical Neurology
  • GBM
  • LANDSCAPE
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Phase I
  • Science & Technology
  • TEMOZOLOMIDE
  • immune checkpoint inhibitor
  • ipilimumab
  • nivolumab

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 1628

end page

  • 1637

volume

  • 26

issue

  • 9